Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD1 Antibody”

1,003 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,003 results

Not applicableStudy completedNCT06607809
What this trial is testing

Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC

Who this might be right for
Metastatic Renal Cell Carcinoma
Dr. Lutfi Kirdar Kartal Training and Research Hospital 99
Testing effectiveness (Phase 2)UnknownNCT05193214
What this trial is testing

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Who this might be right for
Sarcoma, Soft Tissue
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 30
Early research (Phase 1)UnknownNCT05019534
What this trial is testing

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E-mutated /MSS Metastatic Colorectal CancerVemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
West China Hospital 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Post-approval studies (Phase 4)UnknownNCT04134247
What this trial is testing

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Who this might be right for
Relapsed/Refractory Non-Hodgkin's Lymphoma
Shandong Provincial Hospital 120
Early research (Phase 1)Ended earlyNCT02757391
What this trial is testing

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Who this might be right for
Colorectal AdenocarcinomaMetastatic CholangiocarcinomaMetastatic Colorectal Carcinoma+10 more
M.D. Anderson Cancer Center 1
Early research (Phase 1)Study completedNCT03406949
What this trial is testing

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

Who this might be right for
Advanced Solid Tumors
MacroGenics 25
Testing effectiveness (Phase 2)UnknownNCT04676789
What this trial is testing

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Who this might be right for
Extranodal NK/T-cell Lymphoma, Nasal Type
Sun Yat-sen University 30
Testing effectiveness (Phase 2)UnknownNCT03839550
What this trial is testing

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Who this might be right for
Hepatocellular Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 200
Early research (Phase 1)Active Not RecruitingNCT05840224
What this trial is testing

Study of GS-4528 in Adults With Solid Tumors

Who this might be right for
Solid Tumor
Gilead Sciences 182
Testing effectiveness (Phase 2)Active Not RecruitingNCT04238624
What this trial is testing

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT04828486
What this trial is testing

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Who this might be right for
Advanced Hepatocellular CarcinomaBCLC Stage A Hepatocellular CarcinomaBCLC Stage B Hepatocellular Carcinoma+2 more
Mayo Clinic 14
Testing effectiveness (Phase 2)UnknownNCT02886897
What this trial is testing

Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaBladder Cancer+3 more
Sun Yat-sen University 50
Early research (Phase 1)Ended earlyNCT05904496
What this trial is testing

BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 44
Testing effectiveness (Phase 2)Study completedNCT04188860
What this trial is testing

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Who this might be right for
Recurrent Cervical CarcinomaPersistent Advanced Cervical CarcinomaChemotherapy+2 more
Lei Li 34
Early research (Phase 1)Ended earlyNCT04116320
What this trial is testing

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Who this might be right for
MelanomaBreast CancerMerkel Cell Carcinoma+10 more
Craig L Slingluff, Jr 5
Early research (Phase 1)Active Not RecruitingNCT03843359
What this trial is testing

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 97
Early research (Phase 1)Study completedNCT03809767
What this trial is testing

CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Solid TumorLymphoma
CStone Pharmaceuticals 107
Testing effectiveness (Phase 2)UnknownNCT05095636
What this trial is testing

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Who this might be right for
Gastric CancerMetastasis
Fudan University 102
Testing effectiveness (Phase 2)Looking for participantsNCT07277764
What this trial is testing

Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)

Who this might be right for
Nasopharyngeal Carcinoma (NPC)Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital 23
Load More Results